Spruce Biosciences, Inc. (SPRB)
| Market Cap | 148.00M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.97M |
| Shares Out | 2.70M |
| EPS (ttm) | -50.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,866 |
| Open | 56.88 |
| Previous Close | 57.18 |
| Day's Range | 53.75 - 57.17 |
| 52-Week Range | 4.28 - 240.00 |
| Beta | 3.68 |
| Analysts | Strong Buy |
| Price Target | 190.60 (+248.0%) |
| Earnings Date | May 6, 2026 |
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sle... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for SPRB stock is "Strong Buy." The 12-month stock price target is $190.6, which is an increase of 248.00% from the latest price.
News
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel the...
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel the...
Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026
Lead asset for MPS IIIB shows robust clinical benefit and safety, with regulatory progress supported by FDA engagement and a Q4 BLA submission planned. Commercial strategy targets a rare disease market with strong patient advocacy, and financial runway extends into 2027.
Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026
FDA engagement has been positive, supporting accelerated approval based on robust biomarker and clinical data, with BLA submission planned for Q4. Commercial and manufacturing strategies are advancing, and financial runway is expected into 2027, with additional funding options available.
Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences to Present at Upcoming Investor Conferences in March
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
TA-ERT is advancing toward FDA approval for MPS IIIB, with strong clinical data and a BLA submission planned for late 2024. The therapy shows durable efficacy, a favorable safety profile, and significant market potential, with commercialization strategies focused on specialized centers and global partnerships.
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of nove...
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neu...
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.
The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation.
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Transcript: Investor Update
Announced a new strategy focused on TA-ERT for MPS IIIB, with strong clinical data and FDA alignment for accelerated approval. Financial runway extends through 2025, with additional funding needed for BLA submission and commercialization. Plans target a focused launch and global expansion.
Spruce Biosciences Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference
Upcoming December data from two pivotal studies will inform regulatory and clinical strategy for tildacerfont in CAH, with a focus on steroid reduction and androgenic control. The company is also advancing programs in PCOS and MDD, supported by a strong cash position.
Spruce Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024
Multiple late-stage clinical data readouts for tildacerfont in CAH and PCOS are expected in Q4, with strategic partnerships advancing a precision psychiatry program in MDD. Financial runway extends into 2025, and key decisions on pipeline direction will follow upcoming results.
Spruce Biosciences Transcript: Jefferies Global Healthcare Conference
Tildacerfont is advancing in CAH, PCOS, and major depressive disorder, with key data readouts for CAH expected in Q3 and a new phase II depression study starting in Q4. Recent studies show promising biomarker improvements and a strong cash runway through 2025.